Latest Breaking News On - Dopavision gmb - Page 1 : comparemela.com

Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's

Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®,a novel therapeutic approach to manage myopia progression

Dopavision Reports Successful Completion of Enrollment for

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected.

Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active

Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer